Nippon Shinyaku Licenses Prulifloxacin Marketing Rights To Lee’s Pharmaceutical
This article was originally published in PharmAsia News
Executive Summary
Kyoto-based Nippon Shinyaku announced March 3 a licensing agreement on antibacterial drug prulifloxacin with Hong Kong biopharmaceutical company Lee's Pharmaceutical Holdings, which gives Lee's the exclusive marketing rights in China for antibacterial drugs containing prulifloxacin. Nippon Shinyaku will receive an undisclosed upfront payment, milestone payments based on sales achievement and product royalties. An oral broad spectrum fluoroquinolone antibiotic developed by Nippon Shinyaku, prulifloxacin is marketed in Japan by Meiji Seika with the name Sword and by Angelini with the name Unidrox in Europe. (Click here for more - Japanese language
You may also be interested in...
One Drug Outfit On China's Periphery Stands Out From The Crowd Through Innovation
HONG KONG - A famous ability to copy, combined with a chronic shortage of innovation, has long defined China's pharmaceutical industry
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.